Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Interdisciplinary exchange at the DIVI22

The 22nd Congress of the German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI) in Hamburg was well attended with about 5,700 participants – and another complete success for CARL. The CARL Teams from the Sales and Support departments of Resuscitec GmbH once again presented the technical performance features of the CARL System live to many interested parties at the CARL booth in the Congress Center Hamburg from 30 November to 2 December. “It is often the rescue, emergency and intensive care physicians who are first with the resuscitation patient. Especially for patients with refractory cardiac arrest, CARL can provide the decision-makers in an interdisciplinary team on site additional time to implement the best possible and patient-specific therapy”, says Thomas Kraft, CEO of Resuscitec GmbH.

This year’s attendance congress covered a diverse range of topics. In symposia, congress participants were able to learn about the latest status of resuscitation guidelines and innovations in mechanical circulatory support. Personalised ventilation strategies and the use of in- and out-of-hospital extracorporeal procedures were further topics that were in focus at the conference. “Due to the interdisciplinary nature of the visitors, DIVI22 was one of the most successful congresses for us this year. The interaction with users from different medical fields along the rescue chain has once again pushed us decisively forward looking at the coming year”, says Patrick Rauh, Head of Sales of Resuscitec GmbH.

Highlights in the area of intensive care and emergency medicine were the demonstration of the latest generation of ADAC rescue helicopters and the presentation of possible future concepts such as the use of drones in emergencies. In this context, the mountain rescue services Black Forest and Thuringia vividly demonstrated the course of a cable car evacuation.

< Zurück